PK/PD Modelling and Beyond: Impact on Drug Development

被引:17
作者
Breimer, Douwe D. [1 ]
机构
[1] Leiden Univ, Leiden Amsterdam Ctr Drug Res, NL-2300 RA Leiden, Netherlands
关键词
mechanism-based PK; PD models; new drug combinations; PK; PD modeling in drug development; systems pharmacology and therapeutics;
D O I
10.1007/s11095-008-9717-x
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
PK/PD modelling will play an increasingly important role in drug development, because it will identify key properties of a drug in vivo, allowing the characterization and prediction of the time course of drug effects under physiological and pathological conditions (intensity and duration). It has developed from a descriptive to a mechanism-based approach, taking the relevant processes on the causal path between drug administration and drug effect into account. Recent developments and insights from systems biology and systems pharmacology will provide new information on the complexities of disease associated with the identification of multiple targets for drug treatment. This will give rise to new opportunities of drug combinations, which can only be developed rationally through the appropriate application of dynamical systems-based PK/PD models.
引用
收藏
页码:2720 / 2722
页数:3
相关论文
共 14 条
[1]   Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development - The 'Wooden Shoe' paradigm [J].
Breimer, DD ;
Danhof, M .
CLINICAL PHARMACOKINETICS, 1997, 32 (04) :259-267
[2]   Future challenges for drug delivery research [J].
Breimer, DD .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 33 (03) :265-268
[3]   Drug treatment effects on disease progression [J].
Chan, PLS ;
Holford, NHG .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 :625-659
[4]   Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development - Designing informative human pharmacology studies [J].
Cohen, Adam .
CLINICAL PHARMACOKINETICS, 2008, 47 (06) :373-381
[5]  
DANHOF M, 1990, P MEAS KIN IN VIV DR
[6]  
DANHOF M, 1994, P MEAS KIN IN VIV DR
[7]  
DANHOF M, 2002, P MEAS KIN IN VIV DR
[8]  
DANHOF M, 1998, P MEAS KIN IN VIV DR
[9]  
DANHOF M, 2006, P MEAS KIN IN VIV DR
[10]   Mechanism-based pharmacokinetic-pharmacodynamic modeling: Biophase distribution, receptor theory, and dynamical systems analysis [J].
Danhof, Meindert ;
de Jongh, Joost ;
De lange, Elizabeth C. M. ;
Della Pasqua, Oscar ;
Ploeger, Bart A. ;
Voskuyl, Rob A. .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2007, 47 :357-400